GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (FRA:IM8N) » Definitions » Other Current Receivables

Insmed (FRA:IM8N) Other Current Receivables : €0.0 Mil (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Insmed Other Current Receivables?

Insmed's Other Current Receivables for the quarter that ended in Sep. 2024 was €0.0 Mil.


Insmed Other Current Receivables Historical Data

The historical data trend for Insmed's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Other Current Receivables Chart

Insmed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Insmed Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Insmed Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Insmed Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Insmed's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Insmed Business Description

Industry
Traded in Other Exchanges
Address
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Insmed Headlines

No Headlines